Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 01/28/14 → 11/26/18 |
Funding
- Novartis Pharmaceuticals Corporation: $66,726.61
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients
- Skopicki, Hal A (PI)
- Bloom, Michelle (CoPI)
Project: Research